Galectin-1 Induces Hepatocellular Carcinoma EMT and Sorafenib Resistance by Activating FAK/PI3K/AKT Signaling

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2016 Apr 22

PMID 27100895

Citations 129

Authors

P-F Zhang

K-S Li

Y-H Shen

P-T Gao

Z-R Dong

J-B Cai

C Zhang

X-Y Huang

M-X Tian

Z-Q Hu

D-M Gao

J Fan

A-W Ke

G-M Shi

Affiliations

Soon will be listed here.

Abstract

Galectin-1 (Gal-1) is involved in several pathological activities associated with tumor progression and chemoresistance, however, the role and molecular mechanism of Gal-1 activity in hepatocellular carcinoma (HCC) epithelial-mesenchymal transition (EMT) and sorafenib resistance remain enigmatic. In the present study, forced Gal-1 expression promoted HCC progression and sorafenib resistance. Gal-1 elevated αvβ3-integrin expression, leading to AKT activation. Moreover, Gal-1 overexpression induced HCC cell EMT via PI3K/AKT cascade activation. Clinically, our data revealed that Gal-1 overexpression is correlated with poor HCC survival outcomes and sorafenib response. These data suggest that Gal-1 may be a potential therapeutic target for HCC and a biomarker for predicting response to sorafenib treatment.

Citing Articles

Inhibition of Galectin-1 and Androgen Receptor Axis Enhances Enzalutamide Treatment in Enzalutamide Resistant Prostate Cancer.

Wang H, Gao A, Xia R, Wu C, Hsu S, Chen C Cancers (Basel). 2025; 17(3).

PMID: 39941722 PMC: 11816353. DOI: 10.3390/cancers17030351.

Galectins and Liver Diseases.

Mimura S, Morishita A, Oura K, Takuma K, Nakahara M, Tadokoro T Int J Mol Sci. 2025; 26(2).

PMID: 39859504 PMC: 11766161. DOI: 10.3390/ijms26020790.

Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).

Ye G, Ye M, Jin X Am J Cancer Res. 2024; 14(9):4113-4171.

PMID: 39417171 PMC: 11477829. DOI: 10.62347/UJVP4361.

Molecular landscape of kidney allograft tissues data integration portal (NephroDIP): a curated database to improve integration of high-throughput kidney transplant datasets.

Boshart A, Petrovic S, Abovsky M, Pastrello C, Farkona S, Manion K Front Immunol. 2024; 15:1469500.

PMID: 39399491 PMC: 11466753. DOI: 10.3389/fimmu.2024.1469500.

Role of the GalNAc-galectin pathway in the healing of premature rupture of membranes.

Chen J, Liu L, Peng X, Wang Y, Xiang X, Chen Y Mol Med. 2024; 30(1):138.

PMID: 39232672 PMC: 11375961. DOI: 10.1186/s10020-024-00908-6.

References

Huang C, Tang S, Chung L, Yu C, Ho J, Cha T . Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer. J Am Soc Nephrol. 2014; 25(7):1486-95. PMC: 4073433. DOI: 10.1681/ASN.2013070773. View

Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E . MEK in cancer and cancer therapy. Pharmacol Ther. 2013; 141(2):160-71. DOI: 10.1016/j.pharmthera.2013.10.001. View

Hernandez-Gea V, Toffanin S, Friedman S, Llovet J . Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013; 144(3):512-27. PMC: 3578068. DOI: 10.1053/j.gastro.2013.01.002. View

Astorgues-Xerri L, Riveiro M, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S . Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev. 2013; 40(2):307-19. DOI: 10.1016/j.ctrv.2013.07.007. View

Seguin L, Kato S, Franovic A, Camargo M, Lesperance J, Elliott K . An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014; 16(5):457-68. PMC: 4105198. DOI: 10.1038/ncb2953. View

Dufour J . The evasive promise of antiangiogenic therapy. J Hepatol. 2009; 51(5):970-2. DOI: 10.1016/j.jhep.2009.07.006. View

Kannan N, Nguyen L, Eaves C . Integrin β3 links therapy resistance and cancer stem cell properties. Nat Cell Biol. 2014; 16(5):397-9. DOI: 10.1038/ncb2960. View

Zhang P, Shi B, Zhou M, Jiang H, Zhang H, Pan X . Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis. 2014; 5:e991. PMC: 4040687. DOI: 10.1038/cddis.2013.526. View

Carr B . Hepatocellular carcinoma: current management and future trends. Gastroenterology. 2004; 127(5 Suppl 1):S218-24. DOI: 10.1053/j.gastro.2004.09.036. View

10.

Xia L, Huang W, Tian D, Zhu H, Qi X, Chen Z . Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology. 2012; 57(2):610-24. DOI: 10.1002/hep.26029. View

11.

Martinez-Bosch N, Fernandez-Barrena M, Moreno M, Ortiz-Zapater E, Munne-Collado J, Iglesias M . Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res. 2014; 74(13):3512-24. PMC: 4332591. DOI: 10.1158/0008-5472.CAN-13-3013. View

12.

van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F . Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett. 2012; 329(1):74-83. DOI: 10.1016/j.canlet.2012.10.021. View

13.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

14.

Hsu Y, Wu C, Hung J, Lin Y, Huang M, Kuo P . Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin α6β4 and Notch1/Jagged2 signaling pathway. Carcinogenesis. 2013; 34(6):1370-81. DOI: 10.1093/carcin/bgt040. View

15.

Ding W, You H, Dang H, LeBlanc F, Galicia V, Lu S . Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology. 2010; 52(3):945-53. PMC: 3032356. DOI: 10.1002/hep.23748. View

16.

White N, Masui O, Newsted D, Scorilas A, Romaschin A, Bjarnason G . Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. Br J Cancer. 2014; 110(5):1250-9. PMC: 3950857. DOI: 10.1038/bjc.2013.828. View

17.

Ito K, Stannard K, Gabutero E, Clark A, Neo S, Onturk S . Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev. 2012; 31(3-4):763-78. DOI: 10.1007/s10555-012-9388-2. View

18.

Zhu A . Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?. Oncologist. 2006; 11(7):790-800. DOI: 10.1634/theoncologist.11-7-790. View

19.

Berghoff A, Kovanda A, Melchardt T, Bartsch R, Hainfellner J, Sipos B . αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer. Clin Exp Metastasis. 2014; 31(7):841-51. DOI: 10.1007/s10585-014-9675-0. View

20.

Huang X, Ke A, Shi G, Zhang X, Zhang C, Shi Y . αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. Hepatology. 2013; 57(6):2235-47. DOI: 10.1002/hep.26255. View